이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial (TRIFECTA)

2026년 11월 9일 업데이트: University of Washington

Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab in Patients With Muscle Invasive Bladder Cancer (TRIFECTA)

This phase II trial tests the effect of intravesical nadofaragene firadenovec in combination with enfortumab vedotin and pembrolizumab before (neoadjuvant) radical cystectomy in treating patients with muscle invasive bladder cancer. The combination of enfortumab vedotin and pembrolizumab are already considered standard of care in the treatment of muscle invasive bladder cancer. This trial attempts to determine whether the addition of nadofaragene firadenovec to the current standard regiment is safe and can improve oncological outcomes for those with muscle invasive bladder cancer.

Nadofaragene firadenovec, a type of intravesical gene therapy, is a weakened adenovirus that carries a copy of the gene for interferon alfa-2b. This medication gets absorbed by the bladder and stimulates the bladder to naturally create interferon alfa-2b, which is thought to kill bladder cancer. Nadofaragene firadenovec is given in a solution that is placed directly into the bladder (intravesical) using a thin tube called a catheter. It is a medication that is already Food and Drug Administration approved for the treatment of non-muscle invasive bladder cancer.

Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate.

Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread.

Investigators aim to assess whether adding intravesical nadofaragene firadenovec to the current recommended treatment of enfortumab vedotin and pembrolizumab before undergoing a radical cystectomy may be safe, tolerable, and/or effective in treating patients with muscle-invasive bladder cancer.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

OUTLINE:

Patients receive standard of care neoadjuvant therapies for muscle invasive bladder cancer including: enfortumab vedotin intravenously (IV) on days 1 and 8 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 3-4 cycles in the absence of disease progression or unacceptable toxicity. In addition, patients will also receive nadofaragene firadenovec intravesically on day 1 of cycle 1 (one total dose during the entire neoadjuvant period). Starting 4-8 weeks after completion of treatment, patients undergo radical cystectomy (RC) per standard clinical care. Additionally, patients undergo urine and blood sample collection and computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography (PET)/CT throughout the study.

After completion of study treatment, patients are followed for up to 30 days post-cystectomy to monitor for adverse events.

연구 유형

중재적

등록 (추정된)

24

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Jonathan Wright, MD
  • 전화번호: 206-598-4294
  • 이메일: jlwright@uw.edu

연구 장소

    • Washington
      • Seattle, Washington, 미국, 98109
        • Fred Hutch/University of Washington Cancer Consortium
        • 수석 연구원:
          • Jonathan Wright, MD
        • 연락하다:
          • Jonathan Wright, MD
          • 전화번호: 206-598-4294
          • 이메일: jlwright@uw.edu

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age ≥ 18 years at the time of screening
  • Ability to understand and willingness to sign the written informed consent document
  • Patients with confirmed muscle-invasive urothelial carcinoma of the bladder (cT2-4a, N0-1, M0 or cT1, N1, M0), who are planning to undergo RC
  • Pure urothelial or mixed histologic subtypes are allowed if urothelial is the primary histology (regardless of the % of conventional urothelial histology; however, any % of small cell/neuroendocrine is excluded)
  • Eligible to receive neoadjuvant enfortumab vedotin and pembrolizumab (EV-P) per the patient's medical oncologist's discretion
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Hemoglobin ≥ 9 g/dL
  • Absolute neutrophil count of ≥ 1500 cells/uL
  • Platelet count of ≥ 100,000/uL
  • Alanine and aspartate aminotransferase levels ≤ 2.5 x upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 x ULN (≤ 2.5 x ULN for Gilbert syndrome)
  • Creatinine clearance or estimated glomerular filtration rate (GFR) ≥ 30ml/min (using Chronic Kidney Disease Epidemiology Collaboration Formula [CKD-EPI] 2021 or Cockcroft-Gault equation)
  • For patients with evidence of, or history of HIV, chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, the viral load must be undetectable, or the infection must have been treated and cured. Patients are not allowed to be on therapy agents given for HIV, HBV or HCV. Routine testing for HIV, HBV and HCV is not required for patients without such history unless clinically indicated
  • Individuals with prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are allowed to enroll

Exclusion Criteria:

  • cT4b, N2-3, or M1 clinical stage at time of screening
  • Any known concurrent clinically relevant malignancies (discussion with trial principal investigator [PI] can be considered)
  • Prior systemic therapy for MIBC or non-muscle invasive bladder carcinoma (NMIBC)
  • Current or prior use of systemic immunosuppressive medication within 14 days before first dose of investigational product. The following are allowed (not systemic route): intranasal, inhaled, intra-auricular, intra-articular, topical steroids, local steroid injections
  • Pure non-urothelial histology subtype/variant or any neuroendocrine (small or large cell) component
  • Prior treatment with adenovirus-based drugs
  • Known hypersensitivity or allergy to any components of rAd-interferon (IFN)a/Syn3
  • Currently receiving other investigational agent
  • Pregnant or lactating women
  • Inability to comprehend and provide informed consent

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Treatment

Patients receive standard of care neoadjuvant therapies for muscle invasive bladder cancer including: enfortumab vedotin IV on days 1 and 8 and pembrolizumab IV on day 1 of each cycle. In addition, patients also receive nadofaragene firadenovec intravesically on day 1 of cycle 1 (total of 1 dose in neoadjuvant period). Cycles repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Starting 4-8 weeks after treatment, patients undergo RC per standard clinical care. Additionally, patients undergo urine and blood sample collection and CT, MRI or PET/CT throughout the study.

Undergo MRI

다른 이름들:
  • MRI

Given IV

다른 이름들:
  • 키트루다

Undergo CT or PET/CT

다른 이름들:
  • CT
  • 고양이 스캔
  • CT 스캔

Undergo PET/CT

다른 이름들:
  • 애완 동물
  • PET 스캔

Given IV

다른 이름들:
  • 패드체프
  • AGS-22M6E
  • 안티 넥틴 4 ADC ASG-22CE
  • 항-넥틴-4 단클론 항체-약물 컨쥬게이트 AGS-22M6E
  • ASG 22CE

Undergo urine and blood sample collection

다른 이름들:
  • 생물학적 샘플 수집

Given intravesically

다른 이름들:
  • 애드스틸라드린
  • 인스틸라드린
  • 재조합 아데노바이러스-인터페론 SCH 721015
  • 재조합 아데노바이러스-인터페론과 Syn3
  • 재조합 아데노바이러스-인터페론/Syn3
  • SCH 721015

Undergo RC

다른 이름들:
  • RC

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of patients who receive nadofaragene firadenovec and complete at least 2 cycles of enfortumab vedotin and pembrolizumab in the neoadjuvant period followed by radical cystectomy
기간: Within 10 weeks from last neoadjuvant therapy dose

Will be calculated as the number of patients who complete the planned course divided by the total number of enrolled patients who initiate therapy. Exact 95% confidence intervals will be reported. Reasons for non-completion will be summarized descriptively.

Within 10 weeks from last neoadjuvant therapy dose

2차 결과 측정

결과 측정
측정값 설명
기간
Incidence of grade 3 or higher treatment-related adverse events (AE)
기간: From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)

Will be graded by provider-scored toxicity via the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. Will be summarized descriptively, including the number and proportion of patients experiencing at least one grade ≥ 3 AE, and the type, severity, and relatedness of all treatment-related AEs, attributed by agent.

From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)
Incidence of AEs
기간: From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)

Will be summarized by maximum CTCAE grade and relatedness to the treatment.

From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)
Pathologic complete response (pCR) on radical cystectomy (RC) specimen
기간: At time of radical cystectomy (RC), approximately 4-8 weeks following completion of neoadjuvant systemic therapies

Will be defined as the proportion of participants achieving ypT0N0. Will assume the null hypothesis that the true pCR rate is 56 % with the alternative hypothesis of 65%. The observed pCR rate will be reported with an exact 95% confidence interval using the Clopper-Pearson method.

At time of radical cystectomy (RC), approximately 4-8 weeks following completion of neoadjuvant systemic therapies
Downstaging (≤ ypT1N0) on RC specimen
기간: At time of RC, approximately 4-8 weeks following completion of neoadjuvant systemic therapies
At time of RC, approximately 4-8 weeks following completion of neoadjuvant systemic therapies

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Jonathan Wright, MD, Fred Hutch/University of Washington Cancer Consortium

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2027년 6월 1일

연구 완료 (추정된)

2027년 7월 1일

연구 등록 날짜

최초 제출

2026년 1월 6일

QC 기준을 충족하는 최초 제출

2026년 1월 8일

처음 게시됨 (실제)

2026년 1월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

키워드

기타 연구 ID 번호

  • RG1126027
  • NCI-2025-09407 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .